09:00-09:15　Building Trustworthy Medical AI Foundations: XY Health Enterprise AI Data Intelligence Platform
Meishuo Ouyang: Vice President, XY Health

09:15-09:30　Innovative Drugs for Neurological Critical Care and Nerve Repair
Jinhui Chen: CEO, Suzhou GrandKol Pharm

09:30-09:45　MicroRNA (miRNA) Therapies for Aging-Related Diseases
Howe Li: Chairman, Livius Biotech

09:45-10:00　RegenTraceTM: Unlocking the Black Box of Cell Therapy, Redefining the Era of Visualized Cell Therapy
MegaPro: Founder, US

10:00-10:15　The Next Cornerstone for CKD: Phase 2 Data Analysis of Highly Selective Endothelin A Receptor Antagonist SAL0120
Suning Wei: Head of Clinical Development, Metabolism & Nephrology, Shenzhen Salubris Pharmaceuticals

10:15-10:30　Development of Differentiated Anti-infective New Drugs
Donghui Qin: CEO, Phaeno Therapeutics

10:30-10:45　Break

10:45-11:00　Base-Modified Circular RNA Technology and In Vivo CAR Immunotherapy
Liang Qu: Researcher, Fudan University; Founder & Executive Director, Jianjie Biotech

11:00-11:15　R&D of Novel Payloads for Antitumor Conjugated Drugs
Wu Su: Director of Original New Drug Research Center, Greater Bay Area Institute of Precision Medicine (Guangzhou)

11:15-11:30　Autonomous AI Agents for Science: Accelerating Small Molecule & ADCs Discovery
Xiang Wang: Founder and CSO of SynAgentics Biosciences

11:30-11:45　Breaking Through Innate Immunity and Nuclear Envelope Barriers: Non-viral DNA Delivery Opens a New Chapter in Long-acting CGT Therapy
Yuzhe Pan: Founder & CEO, Barbell Therapeutics

11:45-12:00　Highly Selective JAK1 Inhibitor WXFL10203614 Tablets – An Old Target, A New Breakthrough
David Zhang: General Manager's Assistant, Head of Clinical Department, ZHUOHE PHARMACEUTICAL GROUP Co., Ltd.

Investors (in no particular order)
Xiaopeng Fan: Managing Director, Qingda Mingyun Venture Capital
Haiding Yang: Partner, InnoVen Capital
Jin Wan: Founding Partner, Root Venture Partners
Jia Zhuang: Executive Director, ATLATL
Gaopeng Chen: Investment Director, Prosperity7 Ventures
Li Shen: Partner, Chuling Private Equity Fund
More investors to be invited...

13:30-13:35　Opening Remarks
John Chen: DBOP-AI Global Education Institute / Concurrently Director of CIO Era East China Institute

13:35-13:55　AI in MedTech: Northern Europe's Digital Health Revolution
Raivo Kivlenieks: Co-founder, Lexu Care · Estonia / Latvia

13:55-14:15　The Cornerstone of Intelligent Emergence: Reconstructing a New Paradigm for Synergy Among Industry, Academia, Research, Education, and Healthcare in AI + Pharmaceuticals
Yang Yang: Group Office Director and Commercial AI Strategy Lead, Hansoh Pharma

14:15-14:35　Using AI to Enhance KPI Accuracy and Corporate Decision-Making Capabilities in Pharmaceutical Companies
Steven Tian: Head of APAC Marketing, Life Sciences, IR

14:35-14:55　AI Reshaping the Healthcare Value Chain: A New Paradigm for Innovative Drug Commercialization
Yusheng Zhang: Founder & CEO, Apricot Forest

14:55-15:15　Building a GEO System for Pharma — Winning with Integrity
Jing Yi: Founder & CEO, Hua Bai Nuo

15:15-16:00　Panel: Beyond Boundaries, A New Horizon for AI in Biomedicine
Jing Yi (Moderator): Founder & CEO, Hua Bai Nuo
John Chen: DBOP-AI Global Education Institute / Concurrently Director of CIO Era East China Institute
Yusheng Zhang: Founder & CEO, Apricot Forest
Yang Yang: Group Office Director and Commercial AI Strategy Lead, Hansoh Pharma
Peter Xu: CIO, Fortunecare
Humphrey Luo: Associate Director, SAP, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Jason Zhang: CIO, Specially Appointed Lecturer, CIO Era

13:30-14:00　From 1.0 to 2.0: The Paradigm Leap of Chinese Biotech NewCo Global Capitalization
Rui Li: Partner, NewCo Capital

14:00-14:20　Project Initiation Strategy and Transaction Key Points
Jinbin Zhang: Director of External Innovation, Haleon

14:20-15:10　Panel: Opportunities and Challenges of Cross-Border Biotech Transactions Under the New International Landscape
Yingjie Zhao (Moderator): Partner, Han Kun Law Offices
Youchen Chen: Chief Financial Officer, Harbour BioMed
Zhichao Jiang: Partner, PwC Tax & Business Advisory Services
Vince Deng: Partner, Med-Fine Capital

15:10-16:00　Panel: Cold Thinking on BD in the Heat of Global Drug Expansion – A New International Context
Jian Xiong (Moderator): Partner, NewCo Capital
He Zhou: BD Director, Everest Medicines
Wenjun Jiang: BD Director, LianBio (or Federation Bio)
Xin Mei: BD Director, Minwei Biotech

10:00-10:20　The Next Chapter of China-US Biotechnology: Competition, Collaboration and Capital
Brian Yang：Former Executive Editor, Citeline; China Biotech Correspondent, STAT News

10:20-11:50　Fireside Chat: Impacts of U.S. FDA Regulatory Changes on the Biotechnology Industry
Yaning Wang：Founder & CEO, Ruiningkang Pharma; Former Director at FDA
Brian Yang：Former Executive Editor, Citeline; China Biotech Correspondent, STAT News

10:55-11:55　Roundtable: U.S.-China Biotech Competitive Landscape and Global Expansion Strategies
Minhua Chu（Moderator）：Managing Partner, Quanjing Consulting
Brian Yang：Former Executive Editor, Citeline; China Biotech Correspondent, STAT News
Yaning Wang：Founder & CEO, Ruiningkang Biotechnology; Former Director, Clinical Quantitative Pharmacology Division, FDA
Zhimin Zhang：Mentor, QB3/Bakar Bioinnovation Hub, UC Berkeley
Pengcheng Zhu：Founder & CEO, ATLATL Innovation Center
Yang Gu：Partner, Han Kun Law Offices

09:00-10:30　Debate: China's Biotech — Specialized Business Models vs. Fully Integrated Biopharma
Moderator & Organizer: QiuCheng Tao：Investment VP, Yatai Capital
Pro Side:
Nancy Du：Investment Manager, Puhua Capital
Jessie Huang：Partner, Real Power Capital
Matthew Ma：Head of BD, Vigonvita Life Sciences Co., Ltd
Con Side:
Jasen Lu：Head of BD, Tonghua Dongbao Pharmaceutical Co., Ltd.
Yan Ma：Managing Director, CBC Group
Sharon：Head of Business Development Transformation, Pfizer China

10:30-12:00　Panel Discussion: Connecting the World, Driving the Future: Accelerating Industry Transformation Through Cross-Border Biopharma Innovation Ecosystems
Moderator: Sally Sha：Vice President & China Head, Elpis Biopharmaceuticals
Panelists:
Tony Guo：CEO, GoBroad Clinical Research Center, GoBroad Healthcare Group
Tao Yang：Deputy Director of the Life Science & Health Industry Office
Xiaobao Yang：Founder, Chairman and CEO, Gluetacs Therapeutics (Shanghai) Co., Ltd.
Hualong Sun：Chief Strategy Officer, Clinical Service Center
ChengFeng：General Manager, Viedoc Technologies (Shanghai) Co., Ltd.
Xiao chun Chen：CSO and Group VP, JOINN Laboratories
Yan Chen：Founder, CEO, Elpis Biopharmaceuticals

13:00-13:30　Guest Check-in

13:30-13:35　Opening Remarks
Feng Chen: CEO, Bio-Link Capital

13:35-14:00　From Quantity to Quality: Paradigm Shift and the Future of Pharma BD Deals in China
Speaker to Be Confirmed

14:00-14:20　Gene Therapy for Congenital Deafness: From R&D to Clinical Translation
Lu Gao: CEO, Euhearing (Shanghai Youyin Pharmaceutical Co., Ltd.)

14:20-14:40　Topical Anti-HPV Therapeutics
Hongtao Tian: CEO, Beijing Aokesuo Biotechnology Co., Ltd.

14:40-15:00　Intelligent Long-Acting Insulin Delivery Technology
Jiantao Zhang: Research Professor, Ningbo Institute of Materials Technology and Engineering (NIMTE)

15:00-15:20　Addressing Unmet Clinical Needs of Women with HSIL: High-Return, Low-Risk, Non-Invasive Therapeutic FIC Program — U.S. Market Development Opportunities
BaoHua Chen: EVP Finance Board Secretary, Yahuang Pharma

15:20-15:40　Off-the-Shelf CAR-iNKT Precision Therapy: Overcoming the High Cost of CAR-T and the Challenges of Solid Tumors
Shichun Tu: CEO, Suzhou Ruijiesen Biotechnology

15:40-16:00　CQ-0736: A New Modality with Robust Pan-KRAS Anti-Tumor Efficacy, Powered by Glyco TDS™ Platform
Longsheng Hu: Head of Business Development, Suzhou Shengduolikang Pharmaceutical Co., Ltd.

16:00-16:20　First-in-Class AI-Powered Precision Energy Platform for Minimally Invasive Pain Management
Liang Cheng: Partner, Shanghai Wuwei Medical Technology Co., Ltd.

16:20-16:40　CNS-196: Next-Generation Brain Microcirculation–Neurovascular Unit Protectant
Haijian Fu: Chief Scientist, Small Molecules & Director of Molecular Design Institute, Nanjing Zhihe Pharma

16:40-17:00　Expression and Production of Anti-Tumor Therapeutics in Patient Tumor Cells
Guoqing Zhou: Founder & CEO, Rongrui Pharmaceutical

17:00-17:20　Globally Synchronized R&D of Innovative Anti-Cancer Drug FL118 Series
Huiguo Zhao: Capital Operations Officer, Zhaoqing Yikai International Pharmaceutical Research Institute